[HTML][HTML] Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
MF Yuen, S Locarnini, TH Lim, SI Strasser… - Journal of …, 2022 - Elsevier
Background & Aims RNA interference therapy has been shown to reduce hepatitis B surface
antigen (HBsAg) levels in preclinical models, which could confer functional cure in patients
with chronic hepatitis B. This phase IIa trial (ClinicalTrials. gov Identifier: NCT03365947)
assessed the safety and efficacy of the small-interfering RNA JNJ-73763989 (JNJ-3989)
plus a nucleos (t) ide analogue (NA), with/without the capsid assembly modulator JNJ-
56136379 (JNJ-6379) in patients with chronic hepatitis B. Methods Treatment-naïve and NA …
antigen (HBsAg) levels in preclinical models, which could confer functional cure in patients
with chronic hepatitis B. This phase IIa trial (ClinicalTrials. gov Identifier: NCT03365947)
assessed the safety and efficacy of the small-interfering RNA JNJ-73763989 (JNJ-3989)
plus a nucleos (t) ide analogue (NA), with/without the capsid assembly modulator JNJ-
56136379 (JNJ-6379) in patients with chronic hepatitis B. Methods Treatment-naïve and NA …
